Steven Hall, PhD

Board Director

Dr.Hall serves as an independent director at Ten63. Previously Dr. Hall, was a Partner at LV Management Group (Lilly Ventures) for 12 years, and brings a distinguished career in drug discovery and venture capital to Ten63. Among his many successful investments, Dr.Hall was a Series A investor in Kymera and Nimbus, companies that, similar to the goals of Ten63, seek to bring to clinical proof of concept small molecule drugs discovered through new modalities.

Dr.Hall also has deep experience in entrepreneurship and in leading drug discovery programs at both pharma and biotech. Dr.Hall was a co-founder of Esanex and Serenex as well as a senior executive at Sphinx, until its sale to Lilly in 1994, where he became Site Director for Sphinx/Lilly's operations in NC. Hall started his career at Bristol Myers Squibb where he drove multiple drug discovery campaigns from discovery to the clinic.   

Prior to Ten63, Dr.Hall has served on the boards of, nine drug discovery companies, including: Cavion, Cerulean Therapeutics, Esanex, FORMA Therapeutics, Hydra Biosciences, Kymera Therapeutics, Lysosomal Therapeutics, Nimbus Therapeutics, and Numerate.